Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing

Journal of Immunological Methods

Volumn 355, Issue 1-2, 2010, Pages 40-51

  Zhou, Jerry ^a   Belov, Larissa ^a   Huang, Pauline Y ^a   Shin, Joo Shik ^b   Solomon, Michael J ^a,b   Chapuis, Pierre H ^a,c   Bokey, Leslie ^a,c   Chan, Charles ^c   Clarke, Candice ^c   Clarke, Stephen J ^a   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Antibody microarrays; CD antigens; Colorectal cancer; Fluorescence; Leukocytes; Multiplexing

Indexed keywords

ANTIBODY CONJUGATE; FLUORESCENT DYE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PHYCOERYTHRIN; QUANTUM DOT;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER CELL CULTURE; CELL INTERACTION; CLUSTER ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FLUORESCENT DYES; HUMANS; MALE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; QUANTUM DOTS;

ALEXA;

EID: 77951205608     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.01.015     Document Type: Article

References (73)

1. Belov L., Huang P., Barber N., Mulligan S.P., Christopherson R.I. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics 2003, 3:2147.
2. Belov L., Mulligan S.P., Barber N., Woolfson A., Scott M., Stoner K., Chrisp J.S., Sewell W.A., Bradstock K.F., Bendall L., Pascovici D.S., Thomas M., Erber W., Huang P., Sartor M., Young G.A., Wiley J.S., Juneja S., Wierda W.G., Green A.R., Keating M.J., Christopherson R.I. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br. J. Haematol. 2006, 135:184.
3. Bossi P., Viale G., Lee A.K., Alfano R., Coggi G., Bosari S. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 1995, 55:5049.
4. Chaudry M.A., Sales K., Ruf P., Lindhofer H., Winslet M.C. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br. J. Cancer 2007, 96:1013.
5. Chen S., Liu J., Li G., Mo F., Xu X., Zhang T., Zhang X., Li J., Han X., Sun Y. Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis. Scand. J. Gastroenterol. 2008, 43:456.
6. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860.
7. Davis N.C., Newland R.C. Terminology and classification of colorectal adenocarcinoma: the Australian clinico-pathological staging system. Aust. NZ J. Surg. 1983, 53:211.
8. Diaz L.A., Friedman A.W., He X., Kuick R.D., Hanash S.M., Fox D.A. Monocyte-dependent regulation of T lymphocyte activation through CD98. Int. Immunol. 1997, 9:1221.
9. Diederichsen A.C., Stenholm A.C., Kronborg O., Fenger C., Jensenius J.C., Zeuthen J., Christensen P.B., Kristensen T. Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers. Int. J. Cancer 1998, 79:283.
10. Diederichsen A.C., Hjelmborg J.B., Christensen P.B., Zeuthen J., Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol. Immunother. 2003, 52:423.
11. Duffy M.J., van Dalen A., Haglund C., Hansson L., Holinski-Feder E., Klapdor R., Lamerz R., Peltomaki P., Sturgeon C., Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer 2007, 43:1348.
12. Durrant L.G., Chapman M.A., Buckley D.J., Spendlove I., Robins R.A., Armitage N.C. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol. Immunother. 2003, 52:638.
13. Eifel P., Axelson J.A., Costa J., Crowley J., Curran W.J., Deshler A., Fulton S., Hendricks C.B., Kemeny M., Kornblith A.B., Louis T.A., Markman M., Mayer R., Roter D. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer. J. Natl. Canc. Inst. 2001, 93:979. November 1-3, 2000.
14. Ellmark P., Belov L., Huang P., Lee C.S., Solomon M.J., Morgan D.K., Christopherson R.I. Multiplex detection of surface molecules on colorectal cancers. Proteomics 2006, 6:1791.
15. Endo K., Kohnoe S., Tsujita E., Watanabe A., Nakashima H., Baba H., Maehara Y. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res. 2005, 25:3117.
16. Ferrari B.C., Bergquist P.L. Quantum Dots as alternatives to organic fluorophores for Cryptosporidium detection using conventional flow cytometry and specific monoclonal antibodies: lessons learned. Cytometry A. 2007, 71:265.
17. Fielding L.P., Arsenault P.A., Chapuis P.H., Dent O., Gathright B., Hardcastle J.D., Hermanek P., Jass J.R., Newland R.C. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J. Gastroenterol Hepatol. 1991, 6:325.
18. Francoual M., Etienne-Grimaldi M.C., Formento J.L., Benchimol D., Bourgeon A., Chazal M., Letoublon C., Andre T., Gilly N., Delpero J.R., Lasser P., Spano J.P., Milano G. EGFR in colorectal cancer: more than a simple receptor. Ann. Oncol. 2006, 17:962.
19. Fujimoto Y., Nakanishi Y., Sekine S., Yoshimura K., Akasu T., Moriya Y., Shimoda T. CD10 expression in colorectal carcinoma correlates with liver metastasis. Dis. Colon Rectum 2005, 48:1883.
20. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22:969.
21. Ge Y., Elghetany M.T. Urokinase plasminogen activator receptor (CD87): something old, something new. Lab. Hematol. 2003, 9:67.
22. Greenson J.K., Huang S.C., Herron C., Moreno V., Bonner J.D., Tomsho L.P., Ben-Izhak O., Cohen H.I., Trougouboff P., Bejhar J., Sova Y., Pinchev M., Rennert G., Gruber S.B. Pathologic predictors of microsatellite instability in colorectal cancer. Am. J. Surg. Pathol. 2009, 33:126.
23. Hashida H., Takabayashi A., Kanai M., Adachi M., Kondo K., Kohno N., Yamaoka Y., Miyake M. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002, 122:376.
24. Henry L.R., Lee H.O., Lee J.S., Klein-Szanto A., Watts P., Ross E.A., Chen W.T., Cheng J.D. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer. Res. 2007, 13:1736.
25. Hiraga Y., Tanaka S., Haruma K., Yoshihara M., Sumii K., Kajiyama G., Shimamoto F., Kohno N. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncol. 1998, 55:307.
26. Ishida H., Miwa H., Tatsuta M., Masutani S., Imamura H., Shimizu J., Ezumi K., Kato H., Kawasaki T., Furukawa H., Kawakami H. Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer. Cancer Lett. 2004, 207:109.
27. Itzkowitz S.H., Yuan M., Montgomery C.K., Kjeldsen T., Takahashi H.K., Bigbee W.L., Kim Y.S. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989, 49:197.
28. Jankova, L., Clarke, S.J., Molloy, M.P., 2009. Personal communication.
29. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239.
30. Kaganman I. Quantum dots go with the flow. Nat. Methods 2006, 3:662.
31. Koch M., Beckhove P., Op den Winkel J., Autenrieth D., Wagner P., Nummer D., Specht S., Antolovic D., Galindo L., Schmitz-Winnenthal F.H., Schirrmacher V., Buchler M.W., Weitz J. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann. Surg. 2006, 244:986. discussion.
32. Koike N., Todoroki T., Komano H., Shimokama T., Ban S., Ohno T., Fukao K., Watanabe T. Invasive potentials of gastric carcinoma cell lines: role of alpha 2 and alpha 6 integrins in invasion. J. Canc. Res. Clin. Oncol. 1997, 123:310.
33. Koornstra J.J., Kleibeuker J.H., van Geelen C.M., Rijcken F.E., Hollema H., de Vries E.G., de Jong S. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J. Pathol. 2003, 200:327.
34. Laghi L., Bianchi P., Miranda E., Balladore E., Pacetti V., Grizzi F., Allavena P., Torri V., Repici A., Santoro A., Mantovani A., Roncalli M., Malesci A. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 2009, 10:877.
35. Le Naour F., Andre M., Greco C., Billard M., Sordat B., Emile J.F., Lanza F., Boucheix C., Rubinstein E. Profiling of the tetraspanin web of human colon cancer cells. Mol. Cell. Proteomics 2006, 5:845.
36. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605.
37. Ma Q., Su X.G., Wang X.Y., Wan Y., Wang C.L., Yang B., Jin Q.H. Fluorescence resonance energy transfer in doubly-quantum dot labeled IgG system. Talanta 2005, 67:1029.
38. Malhotra S., Newman E., Eisenberg D., Scholes J., Wieczorek R., Mignatti P., Shamamian P. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: a possible mechanism of neoplastic progression. Dis. Colon Rectum 2002, 45:537.
39. Matsushita K., Takenouchi T., Shimada H., Tomonaga T., Hayashi H., Shioya A., Komatsu A., Matsubara H., Ochiai T. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Sci. 2006, 97:57.
40. Mavligit G.M., Estrov Z. CA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen. Am. J. Clin. Oncol. 2000, 23:213.
41. Miyanaga K., Kato Y., Nakamura T., Matsumura M., Amaya H., Horiuchi T., Chiba Y., Tanaka K. Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res. 2002, 22:3941.
42. Mori M., Mimori K., Shiraishi T., Haraguchi M., Ueo H., Barnard G.F., Akiyoshi T. Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin. Cancer Res. 1998, 4:1507.
43. Nagy N., Legendre H., Engels O., Andre S., Kaltner H., Wasano K., Zick Y., Pector J.C., Decaestecker C., Gabius H.J., Salmon I., Kiss R. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 2003, 97:1849.
44. Newland R.C., Chapuis P.H., Pheils M.T., MacPherson J.G. The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer 1981, 47:1424.
45. Ngan C.Y., Yamamoto H., Seshimo I., Ezumi K., Terayama M., Hemmi H., Takemasa I., Ikeda M., Sekimoto M., Monden M. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J. Surg. Oncol. 2007, 95:652.
46. Nyilas E., Chiu T.H., Herzlinger G.A. Thermodynamics of native protein/foreign surface interactions. I. Calorimetry of the human gamma-globulin/glass system. Trans. Am. Soc. Artif. Intern. Organs 1974, 20:480.
47. Okazaki K., Nakayama Y., Shibao K., Hirata K., Nagata N., Itoh H. Enhancement of metastatic activity of colon cancer as influenced by expression of cell surface antigens. J. Surg. Res. 1998, 78:78.
48. Ostenstad B., Lea T., Schlichting E., Harboe M. Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area. Gut 1994, 35:382.
49. Park D.I., Oh S.J., Park S.H., Yun J.W., Kim H.J., Cho Y.K., Sung I.K., Sohn C.I., Jeon W.K., Kim B.I., Cho E.Y., Kim E.J., Chae S.W., Sohn J.H., Kim J.J. Clinical significance of HER-2/neu expression in colon cancer. Korean J. Gastroenterol 2004, 44:147.
50. Pearson J.P., Allen A., Hutton D.A. Rheology of mucin. Methods Mol. Biol. 2000, 125:99.
51. Prall F., Duhrkop T., Weirich V., Ostwald C., Lenz P., Nizze H., Barten M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum. Pathol. 2004, 35:808.
52. Resch-Genger U., Grabolle M., Cavaliere-Jaricot S., Nitschke R., Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat. Methods. 2008, 5:763.
53. Shibata D., Reale M.A., Lavin P., Silverman M., Fearon E.R., Steele G., Jessup J.M., Loda M., Summerhayes I.C. The DCC protein and prognosis in colorectal cancer. N. Engl. J. Med. 1996, 335:1727.
54. Shinohara M., Ohyama N., Murata Y., Okazawa H., Ohnishi H., Ishikawa O., Matozaki T. CD47 regulation of epithelial cell spreading and migration, and its signal transduction. Cancer. Sci. 2006, 97:889.
55. Singh P. Role of Annexin-II in GI cancers: interaction with gastrins/progastrins. Cancer Lett. 2007, 252:19.
56. Sordat I., Decraene C., Silvestre T., Petermann O., Auffray C., Pietu G., Sordat B. Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells. Lab. Invest. 2002, 82:1715.
57. Speetjens F.M., de Bruin E.C., Morreau H., Zeestraten E.C., Putter H., van Krieken J.H., van Buren M.M., van Velzen M., Dekker-Ensink N.G., van de Velde C.J., Kuppen P.J. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol. Immunother. 2008, 57:601.
58. Steinert R., Buschmann T., van der Linden M., Fels L.M., Lippert H., Reymond M.A. The role of proteomics in the diagnosis and outcome prediction in colorectal cancer. Technol. Cancer. Res. Treat. 2002, 1:297.
59. Strater J., Hinz U., Walczak H., Mechtersheimer G., Koretz K., Herfarth C., Moller P., Lehnert T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer. Res. 2002, 8:3734.
60. Strater J., Hinz U., Hasel C., Bhanot U., Mechtersheimer G., Lehnert T., Moller P. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005, 54:661.
61. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Vardiman J.W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC WHO Classification of Tumours, No 2 2008, Fourth Edition.
62. Traicoff J.L., De Marchis L., Ginsburg B.L., Zamora R.E., Khattar N.H., Blanch V.J., Plummer S., Bargo S.A., Templeton D.J., Casey G., Kaetzel C.S. Characterization of the human polymeric immunoglobulin receptor (PIGR) 3'UTR and differential expression of PIGR mRNA during colon tumorigenesis. J. Biomed. Sci. 2003, 10:792.
63. Ueda J., Semba S., Chiba H., Sawada N., Seo Y., Kasuga M., Yokozaki H. Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 2007, 74:32.
64. Watson N.F., Durrant L.G., Madjd Z., Ellis I.O., Scholefield J.H., Spendlove I. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol. Immunother. 2006, 55:973.
65. Watson N.F., Spendlove I., Madjd Z., McGilvray R., Green A.R., Ellis I.O., Scholefield J.H., Durrant L.G. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int. J. Cancer 2006, 118:1445.
66. Weichert W., Knosel T., Bellach J., Dietel M., Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J. Clin. Pathol. 2004, 57:1160.
67. Weichert W., Denkert C., Burkhardt M., Gansukh T., Bellach J., Altevogt P., Dietel M., Kristiansen G. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin. Cancer. Res. 2005, 11:6574.
68. Weitz J., Koch M., Debus J., Hohler T., Galle P.R., Buchler M.W. Colorectal cancer. Lancet 2005, 365:153.
69. Wielenga V.J., Heider K.H., Offerhaus G.J., Adolf G.R., van den Berg F.M., Ponta H., Herrlich P., Pals S.T. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993, 53:4754.
70. Xiao G.G., Recker R.R., Deng H.W. Recent Advances in Proteomics and Cancer Biomarker Discovery. Clin. Med.: Oncol. 2008 2008.
71. Yamada N., Chung Y.S., Maeda K., Sawada T., Ikehara T., Nishino H., Okuno M., Sowa M. Increased expression of sialyl Lewis A and sialyl Lewis X in liver metastases of human colorectal carcinoma. Invasion Metastasis 1995, 15:95.
72. Yang Y.H., Dudoit S., Luu P., Lin D.M., Peng V., Ngai J., Speed T.P. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002, 30:15.
73. Zajac A., Song D., Qian W., Zhukov T. Protein microarrays and quantum dot probes for early cancer detection. Colloids Surf. B. Biointerfaces 2007, 58:309.